← Back to Search

Unknown

A Study of LY3561774 in Participants With Dyslipidemia

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to week 53

Summary

This trial is testing a new medication called LY3561774 to see if it is safe and effective for people with high blood fat levels, including Japanese participants. The study will check how the body handles the medication and its impact on blood fat levels.

Eligible Conditions
  • Dyslipidemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to week 53
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to week 53 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PD: Change From Baseline in Fasting Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C)
PK: Maximum Observed Drug Concentration (Cmax) of LY3561774
PK: Time of Maximum Observed Concentration (Tmax) of LY3561774
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3561774 (Part C)Experimental Treatment1 Intervention
Single doses of LY3561774 administered SC in Japanese Participants.
Group II: LY3561774 (Part B)Experimental Treatment1 Intervention
Repeat doses of LY3561774 administered SC.
Group III: LY3561774 (Part A)Experimental Treatment1 Intervention
Single ascending doses of LY3561774 administered subcutaneously (SC).
Group IV: Placebo (Part A, B & C)Placebo Group1 Intervention
Placebo administered SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3561774
2020
Completed Phase 2
~280

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,679 Previous Clinical Trials
3,465,679 Total Patients Enrolled
4 Trials studying Dyslipidemia
1,051 Patients Enrolled for Dyslipidemia
Study DirectorEli Lilly and Company
1,389 Previous Clinical Trials
428,094 Total Patients Enrolled
2 Trials studying Dyslipidemia
499 Patients Enrolled for Dyslipidemia
~15 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top